Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and Recrudescence

ecteinascidin 743 has been researched along with Recrudescence in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's8 (88.89)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colombo, N2
González, A1
Alfaro, V; Chan, S; Colombo, N; Filipczyk-Cisarz, E; Gómez, J; Hagberg, H; Kaye, SB; Kong, B; Lebedinsky, C; Monk, BJ; Parekh, T; Park, YC; Poveda, A; Roy, M; Tjulandin, S; Vergote, I1
Chan, S; Colombo, N; Filipczyk-Cisarz, E; Hagberg, H; Kaye, SB; Kong, B; Lebedinsky, C; Monk, BJ; Nieto, A; Parekh, T; Park, YC; Poveda, A; Roy, M; Santabárbara, P; Tjulandin, S; Vergote, I1
González Martín, A1
Benjamin, I; Dalton, H; Monk, BJ; Tanović, A1
Aikin, A; Balis, FM; Bayever, E; Chuk, MK; Fox, E; Whitcomb, T; Widemann, BC; Zannikos, P1
Sabbatini, P1

Reviews

5 review(s) available for ecteinascidin 743 and Recrudescence

ArticleYear
When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Future oncology (London, England), 2017, Volume: 13, Issue:23s

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Retreatment; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2017
Increasing the chances for platinum-sensitive ovarian cancer patients.
    Future oncology (London, England), 2013, Volume: 9, Issue:12 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2013
Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21 Suppl 1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dioxoles; Doxorubicin; Female; Humans; Liposomes; Ovarian Neoplasms; Patient Compliance; Quality of Life; Recurrence; Tetrahydroisoquinolines; Trabectedin

2011
Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21 Suppl 1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Multicenter Studies as Topic; Ovarian Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Recurrence; Tetrahydroisoquinolines; Trabectedin

2011
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Current pharmaceutical design, 2012, Volume: 18, Issue:25

    Topics: Antineoplastic Agents; Dioxoles; Female; Humans; Ovarian Neoplasms; Recurrence; Tetrahydroisoquinolines; Trabectedin

2012

Trials

3 trial(s) available for ecteinascidin 743 and Recrudescence

ArticleYear
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2011
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2011
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:5

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Child; Dexamethasone; Dioxoles; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Recurrence; Tetrahydroisoquinolines; Time Factors; Trabectedin

2012

Other Studies

1 other study(ies) available for ecteinascidin 743 and Recrudescence

ArticleYear
New agents and new formulations for the treatment of ovarian cancer.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A

2005